𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Use of androgen deprivation therapy for metastatic prostate cancer in older men

✍ Scribed by Nancy L. Keating; A. James O’Malley; Mary McNaughton-Collins; William K. Oh; Matthew R. Smith

Book ID
109053772
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
139 KB
Volume
101
Category
Article
ISSN
1464-4096

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Androgen deprivation therapy increases c
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
✍ Christopher S. Saigal; John L. Gore; Tracey L. Krupski; Janet Hanley; Matthias S 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

## Abstract ## BACKGROUND. The use of androgen deprivation therapy (ADT) in the treatment of men with prostate cancer has risen sharply. Although cardiovascular disease is the most common reason for death among men with prostate cancer who do not die of the disease itself, data regarding the effec

Does androgen-deprivation therapy accele
Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? : A conceptual review
✍ Kathryn Bylow; Supriya G. Mohile; Walter M. Stadler; William Dale 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 1 views

## Abstract The majority of men with prostate cancer are aged ≥65 years. Men, as they age, are more likely to suffer from impaired physical function. The standard treatment for recurrent prostate cancer is androgen‐deprivation therapy (ADT). Well‐established toxicities from ADT include lean weight